Therapeutic Targeting of MERTK and BCL-2 in T-Cell and Early T-Precursor Acute Lymphoblastic Leukemia.

A repeat experiment in this model using the same dose of MRX-2843 yielded similar results ( Figure S2 ); although, in this case, the prolongation in median survival seen in mice treated with MRX-2843 did not reach statistical significance. 3.7.

also in 111,027 other papers